venBio
San Francisco, Californiavenbio.com
Overview
venBio is a life sciences investment firm partnering with industry leaders to build game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs. They are mindful of potential acquisition partners from the outset, and they ensure that their companies are best positioned to meet their requirements. This includes intellectual property (IP), chemistry, manufacturing (CMC), and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oak Hill Bio | Jun 2026 | Series A | Lead |
| Candid Therapeutics, Inc. | Mar 2026 | PIPE | Co-investor |
| Caldera Therapeutics | Jan 2026 | Series A Extension | Co-investor |
| Parabilis Medicines | Jan 2026 | Series F | Co-investor |
| Fog Pharmaceuticals | Jan 2026 | Series F | Co-investor |
Key People
Richard Gaster
Managing Partner
Jaume Pons
Venbio Venture Partner
Yvonne Yamanaka
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
